---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-24-000055"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T03:11:12.910301+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ANI Pharmaceuticals Q1 2024: record revenue $137.4M, EPS $0.82; reiterates FY guidance

## Summary
- Q1 net revenue $137.4M (+28.7% YoY); GAAP diluted EPS $0.82 vs $0.06; adjusted non-GAAP EPS $1.21.
- Rare Disease segment (Cortrophin Gel) revenue $36.9M, up 126.2% YoY on higher volume.
- Generics, Established Brands and Other segment revenue $100.5M, up 11.1% YoY; launched six new generics.
- FY2024 guidance reaffirmed: revenue $520M-$542M; adjusted EBITDA $135M-$145M; adjusted EPS $4.26-$4.67.
- Ended quarter with $228.6M cash; sold Oakville facility for $14.2M, recognized $9.7M gain on CG Oncology IPO.

## SEC filing metadata
- accession: 0001023024-24-000055
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000055/0001023024-24-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000055/ani-20240510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-24-000055
- JSON: https://secwatch.observer/filing/0001023024-24-000055.json
- Plain text: https://secwatch.observer/filing/0001023024-24-000055.txt

## Key facts
- Earnings Releases
  ANI PHARMACEUTICALS INC reported the quarter ended March 31, 2024 results: revenue $137.4 million, net income $17.8 million, EPS $0.82. Guidance reaffirmed.
  - Period: the quarter ended March 31, 2024
  - Revenue: $137.4 million
  - Net income: $17.8 million
  - EPS: $0.82
  - Guidance: reaffirmed
  - Result: reported results
  source text: ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance • Generated record quarterly net revenues of $137.4 million, representing year-over-year growth of 28.7%, net income to common shareholders of $17.8 million, and GAAP diluted earnings per share of $0.82
  evidence_url: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000055/0001023024-24-000055-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.